Clinical Trial Update: Restarting Triple Therapy With Robust Monitoring for Adverse Events (RETRIAL)

View source ↗

Summary

A cystic fibrosis clinical trial is restarting a triple-drug therapy with enhanced monitoring for adverse events. The study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Snippet

Sponsor: Boston Children's Hospital | Conditions: Cystic Fibrosis | Status: RECRUITING